Opus Genetics (IRD) Debt Ratio (2019 - 2026)

Opus Genetics (IRD) posted quarterly Debt Ratio of 0.02 for Q1 2026, down 20.17% quarter-over-quarter from 0.02 in Q4 2025.

Analysis

Opus Genetics (IRD) Debt Ratio (2019 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Debt Ratio for 4 consecutive years, with 0.02 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.02; the TTM figure through Mar 2026 stood at 0.02 (changed N/A YoY), while the FY2025 annual figure was 0.02, changed N/A from the prior year.
Debt Ratio slipped to 0.02 in Q1 2026 per IRD's latest filing, from 0.02 in the prior quarter.
Across five years, Debt Ratio topped out at 0.03 in Q3 2025 and bottomed at 0.01 in Q1 2022.
Historically, Debt Ratio has averaged 0.02 across 3 years, with a median of 0.02 in 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	Opus Genetics	446.86 Mn	358.05 Mn	-	0.38

Historic Data

Download Data